{"id":"pd-1-blocking-antibody","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Fatigue"},{"rate":"15–25","effect":"Diarrhea"},{"rate":"10–20","effect":"Nausea"},{"rate":"3–5","effect":"Immune-related pneumonitis"},{"rate":"2–5","effect":"Immune-related hepatitis"},{"rate":"10–15","effect":"Rash"},{"rate":"10–15","effect":"Decreased appetite"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PD-1 is an inhibitory receptor on T cells that cancer cells exploit to evade immune detection by engaging its ligands (PD-L1/PD-L2). By blocking PD-1 with a monoclonal antibody, the drug releases the 'brakes' on the immune system, restoring T cell activation, proliferation, and anti-tumor cytotoxicity. This mechanism has proven effective across multiple solid and hematologic malignancies.","oneSentence":"This drug blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:57.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indications under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT06594991","phase":"PHASE2","title":"A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-10","conditions":"Advanced Melanoma","enrollment":88},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT06325683","phase":"PHASE2","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-11-08","conditions":"Progressive Glioblastoma, Recurrent Glioblastoma","enrollment":184},{"nctId":"NCT07492914","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-20","conditions":"Resected Head and Neck Cancer","enrollment":30},{"nctId":"NCT07281924","phase":"PHASE1, PHASE2","title":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Metastatic Melanoma, Liver Metastases","enrollment":15},{"nctId":"NCT07488533","phase":"PHASE2","title":"Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Non-Clear Cell Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT07488572","phase":"PHASE2","title":"Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2025-11-01","conditions":"Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT04181788","phase":"PHASE1, PHASE2","title":"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-03-18","conditions":"Advanced Malignancies, Non-small-cell Lung Cancer","enrollment":155},{"nctId":"NCT07403136","phase":"PHASE2","title":"Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT04943848","phase":"PHASE1","title":"rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2022-01-10","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":36},{"nctId":"NCT02998268","phase":"PHASE2","title":"Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2017-03-07","conditions":"Esophageal Adenocarcinoma","enrollment":42},{"nctId":"NCT02648282","phase":"PHASE2","title":"Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-07-18","conditions":"Pancreatic Cancer","enrollment":58},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT04301778","phase":"PHASE2","title":"Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-08-24","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":5},{"nctId":"NCT07090148","phase":"PHASE1","title":"Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-03-03","conditions":"Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer","enrollment":14},{"nctId":"NCT05514132","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-23","conditions":"Advanced Solid Tumours","enrollment":14},{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT06239727","phase":"PHASE3","title":"Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-01","conditions":"Nasopharyngeal Carcinoma","enrollment":593},{"nctId":"NCT05290597","phase":"PHASE1","title":"A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-08-22","conditions":"Solid Malignancies or Lymphomas","enrollment":40},{"nctId":"NCT05467670","phase":"PHASE2","title":"Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexander B Olawaiye, MD","startDate":"2023-03-30","conditions":"Ovarian Cancer","enrollment":16},{"nctId":"NCT03514017","phase":"PHASE2","title":"Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-05-31","conditions":"Chronic Lymphocytic Leukemia","enrollment":5},{"nctId":"NCT07223541","phase":"PHASE2","title":"Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-01-15","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":72},{"nctId":"NCT04735978","phase":"PHASE1","title":"Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours","status":"ACTIVE_NOT_RECRUITING","sponsor":"Replimune Inc.","startDate":"2020-12-29","conditions":"Advanced Solid Tumor","enrollment":123},{"nctId":"NCT04969887","phase":"PHASE2","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2021-08-03","conditions":"Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm","enrollment":240},{"nctId":"NCT04336241","phase":"PHASE1","title":"Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Replimune Inc.","startDate":"2019-10-17","conditions":"Cancer","enrollment":36},{"nctId":"NCT04104893","phase":"PHASE2","title":"A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-02-20","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":40},{"nctId":"NCT05414032","phase":"PHASE2","title":"Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-07-12","conditions":"Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)","enrollment":102},{"nctId":"NCT06546553","phase":"PHASE1","title":"A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-09-06","conditions":"Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":10},{"nctId":"NCT04150900","phase":"PHASE2","title":"1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2020-01-13","conditions":"Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT06581406","phase":"PHASE2, PHASE3","title":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-12-17","conditions":"Metastatic Uveal Melanoma","enrollment":280},{"nctId":"NCT03123276","phase":"PHASE1, PHASE2","title":"Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma","status":"COMPLETED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2017-11-29","conditions":"Sarcoma","enrollment":25},{"nctId":"NCT03767348","phase":"PHASE2","title":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Replimune Inc.","startDate":"2017-09-20","conditions":"Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC)","enrollment":340},{"nctId":"NCT07405190","phase":"PHASE2","title":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-08-04","conditions":"Lung Cancer (NSCLC), Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer (Non-Small Cell)","enrollment":46},{"nctId":"NCT07230613","phase":"PHASE2","title":"Neo-adjuvant Immunotherapy in Patients With Localized Melanoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2026-01-12","conditions":"Cutaneous Melanoma, Stage III, Mucosal Melanoma","enrollment":50},{"nctId":"NCT03316573","phase":"PHASE2","title":"Pembrolizumab in Neoplasms or Lymphomas","status":"SUSPENDED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-12-07","conditions":"Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma","enrollment":18},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT03851614","phase":"PHASE2","title":"Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-04-08","conditions":"Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma","enrollment":90},{"nctId":"NCT03203473","phase":"PHASE2","title":"Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Toni Choueiri, MD","startDate":"2017-10-26","conditions":"Renal Cancer","enrollment":85},{"nctId":"NCT07388758","phase":"PHASE2","title":"Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":37},{"nctId":"NCT06624475","phase":"PHASE2","title":"Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-08-21","conditions":"Basal Cell Carcinoma","enrollment":30},{"nctId":"NCT07224022","phase":"PHASE2","title":"Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"John Strickler, M.D.","startDate":"2026-02","conditions":"Colon Cancer","enrollment":24},{"nctId":"NCT05814666","phase":"PHASE2","title":"Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC","status":"TERMINATED","sponsor":"Flamingo Therapeutics NV","startDate":"2023-05-30","conditions":"HNSCC","enrollment":69},{"nctId":"NCT04340882","phase":"PHASE2","title":"Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-06-05","conditions":"Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8","enrollment":30},{"nctId":"NCT03543189","phase":"PHASE1, PHASE2","title":"Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-10-03","conditions":"Prostate Cancer, Prostate Disease","enrollment":44},{"nctId":"NCT03356470","phase":"","title":"Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-02","conditions":"Melanoma","enrollment":5},{"nctId":"NCT04989946","phase":"PHASE1, PHASE2","title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-12-16","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT03082534","phase":"PHASE2","title":"Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2017-03-28","conditions":"HNSCC, Lip SCC, Oral Cavity Cancer","enrollment":78},{"nctId":"NCT05751798","phase":"PHASE1, PHASE2","title":"Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas","status":"RECRUITING","sponsor":"OSE Immunotherapeutics","startDate":"2022-12-20","conditions":"Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)","enrollment":41},{"nctId":"NCT04028063","phase":"PHASE2","title":"Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-01-28","conditions":"Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma","enrollment":65},{"nctId":"NCT06599619","phase":"","title":"Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi","status":"RECRUITING","sponsor":"John Kirkwood","startDate":"2025-02-20","conditions":"Melanoma","enrollment":30},{"nctId":"NCT04165317","phase":"PHASE3","title":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-12-30","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":1068},{"nctId":"NCT04995003","phase":"PHASE1","title":"HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2021-12-07","conditions":"Sarcoma, HER-2 Protein Overexpression, Osteosarcoma","enrollment":25},{"nctId":"NCT03752333","phase":"PHASE2","title":"Trial of Pembrolizumab in Cancer of Unknown Primary","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-02-22","conditions":"Cancer of Unknown Primary Site","enrollment":35},{"nctId":"NCT03333616","phase":"PHASE2","title":"Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-12-28","conditions":"Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder","enrollment":100},{"nctId":"NCT02408861","phase":"PHASE1","title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-10-21","conditions":"Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection","enrollment":79},{"nctId":"NCT03891953","phase":"PHASE1","title":"Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Carcinoma, Non-Small-Cell Lung, Melanoma, Nasopharyngeal Carcinoma","enrollment":98},{"nctId":"NCT04360941","phase":"PHASE1","title":"PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2020-08-11","conditions":"Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer","enrollment":45},{"nctId":"NCT02856425","phase":"PHASE1","title":"Trial Of Pembrolizumab And Nintedanib","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-11-10","conditions":"Patients With Any Advanced Solid Tumors","enrollment":196},{"nctId":"NCT04725474","phase":"PHASE1, PHASE2","title":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CatalYm GmbH","startDate":"2020-12-09","conditions":"Solid Tumor, Adult","enrollment":263},{"nctId":"NCT06076837","phase":"PHASE1","title":"The Seven Trial: Exploiting the Unfolded Protein Response","status":"ACTIVE_NOT_RECRUITING","sponsor":"HonorHealth Research Institute","startDate":"2025-01-09","conditions":"Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic","enrollment":6},{"nctId":"NCT05317000","phase":"PHASE2","title":"5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC","status":"RECRUITING","sponsor":"Barbara Burtness","startDate":"2023-03-23","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":50},{"nctId":"NCT05034536","phase":"PHASE2","title":"PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-07","conditions":"Metastatic Melanoma","enrollment":36},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT05405595","phase":"PHASE1, PHASE2","title":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Adagene Inc","startDate":"2022-06-15","conditions":"Advanced/Metastatic Solid Tumors","enrollment":186},{"nctId":"NCT05387512","phase":"","title":"A Real World Study of β2-Adrenergic Blocker Plus PD-1 Inhibitor in Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Affiliated Hospital of Nantong University","startDate":"2022-01-12","conditions":"Lung Cancer","enrollment":59},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":"Gastric Cancer Stage III","enrollment":74},{"nctId":"NCT07247786","phase":"PHASE2","title":"Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)","status":"NOT_YET_RECRUITING","sponsor":"Fundación GECP","startDate":"2026-03-15","conditions":"Non Small Cell Lung Cancer, Respiratory Tract Neoplasm","enrollment":68},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT07146230","phase":"PHASE2","title":"The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-03-01","conditions":"Non-small Cell Lung Cancer","enrollment":52},{"nctId":"NCT03161431","phase":"PHASE1","title":"SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syntrix Biosystems, Inc.","startDate":"2019-06-12","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":77},{"nctId":"NCT06584435","phase":"PHASE2","title":"A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2022-10-10","conditions":"High-risk Renal Cell Carcinoma","enrollment":100},{"nctId":"NCT03391479","phase":"PHASE2","title":"A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2018-08-15","conditions":"Penile Cancer, Advanced Cancer, Metastatic Cancer","enrollment":25},{"nctId":"NCT07031765","phase":"PHASE1","title":"Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-07-25","conditions":"Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma","enrollment":12},{"nctId":"NCT06514898","phase":"PHASE1","title":"Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-05-05","conditions":"Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma","enrollment":12},{"nctId":"NCT03388632","phase":"PHASE1","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-05","conditions":"Metastatic Solid Tumors, Treatment-Refractory Cancers","enrollment":31},{"nctId":"NCT04688658","phase":"PHASE1, PHASE2","title":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","status":"TERMINATED","sponsor":"John Kirkwood","startDate":"2021-10-06","conditions":"Unresectable Melanoma","enrollment":13},{"nctId":"NCT06494579","phase":"PHASE1, PHASE2","title":"Lamivudine for Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Marron","startDate":"2024-09-26","conditions":"Relapsed/Refractory Solid Tumors","enrollment":12},{"nctId":"NCT04207086","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2020-11-11","conditions":"Melanoma Stage III","enrollment":21},{"nctId":"NCT03347838","phase":"PHASE2","title":"Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2019-01-30","conditions":"Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer","enrollment":19},{"nctId":"NCT06794775","phase":"PHASE3","title":"SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma","status":"RECRUITING","sponsor":"Hildur Helgadottir","startDate":"2025-07-10","conditions":"Malignant Melanoma Stage III","enrollment":128},{"nctId":"NCT02374242","phase":"PHASE2","title":"Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2014-11-04","conditions":"Melanoma, Brain Metastases","enrollment":76},{"nctId":"NCT04916002","phase":"PHASE2","title":"A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-11-30","conditions":"Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma","enrollment":77},{"nctId":"NCT04090528","phase":"PHASE2","title":"pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2019-10-21","conditions":"Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer","enrollment":60},{"nctId":"NCT06121180","phase":"PHASE2","title":"Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-04","conditions":"Metastatic Uveal Melanoma","enrollment":32},{"nctId":"NCT04248569","phase":"PHASE1","title":"DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-04-20","conditions":"Fibrolamellar Hepatocellular Carcinoma (FLC)","enrollment":56},{"nctId":"NCT06843434","phase":"PHASE2","title":"A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-02-20","conditions":"Microsatellite Stable Rectal Carcinoma, Locally Advanced Rectal Adenocarcinoma","enrollment":40},{"nctId":"NCT05723055","phase":"PHASE2","title":"Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-05-03","conditions":"Hodgkin Lymphoma","enrollment":9},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT07244705","phase":"PHASE1, PHASE2","title":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","status":"RECRUITING","sponsor":"Anbogen Therapeutics, Inc.","startDate":"2025-11","conditions":"Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC)","enrollment":66},{"nctId":"NCT05631899","phase":"PHASE1","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V","enrollment":9},{"nctId":"NCT04725331","phase":"PHASE1, PHASE2","title":"A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors","status":"TERMINATED","sponsor":"Transgene","startDate":"2021-02-25","conditions":"Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma","enrollment":31},{"nctId":"NCT06917573","phase":"PHASE2","title":"PALACE: Cemiplimab Trial According to ctDNA Levels","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2025-07-29","conditions":"Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer","enrollment":63},{"nctId":"NCT04520711","phase":"PHASE1","title":"Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2022-02-08","conditions":"Malignant Epithelial Neoplasms","enrollment":24},{"nctId":"NCT06177522","phase":"PHASE2","title":"Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinling Hospital, China","startDate":"2025-11-30","conditions":"Pancreatic Cancer, Neoadjuvant Therapy","enrollment":30},{"nctId":"NCT05935748","phase":"PHASE2","title":"Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)","status":"TERMINATED","sponsor":"NiKang Therapeutics, Inc.","startDate":"2023-07-28","conditions":"ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer","enrollment":18},{"nctId":"NCT06698250","phase":"PHASE2","title":"Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2024-12-18","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06249048","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab","status":"RECRUITING","sponsor":"Strand Therapeutics Inc.","startDate":"2024-05-03","conditions":"Advanced Solid Tumor","enrollment":108}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":80,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JS001","irradiation","PD-1 Blockade","PD-1 blockade","Camrelizumab"],"phase":"phase_3","status":"active","brandName":"PD-1 blocking antibody","genericName":"PD-1 blocking antibody","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pembrolizumab is a PD-1 blocking antibody used to treat various types of cancer, including pleural mesothelioma, breast cancer, and angiosarcoma. It is administered as a small molecule intervention, typically in combination with other treatments such as gemcitabine and vinorelbine.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}